US Preventive Task Force Stalls, Leaving Cancer Screenings and Insurance Coverage in Limbo

The US Preventive Services Task Force (USPSTF) has faced significant disruptions in 2025, raising concerns about its ability to guide national health policies. The independent panel, which usually issues 20 to 25 annual recommendations, released only five last year and has not met since March. Meanwhile, key positions remain unfilled, and its annual report to Congress—critical for shaping research funding—was never submitted.

The slowdown began early in the year under Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. His administration has prioritised addressing what it calls 'the root causes of the chronic disease epidemic', shifting focus toward vaccine policies and dietary guidelines. As a result, the USPSTF's usual workflow has stalled, with scheduled meetings in July and November cancelled.

Staffing issues have added to the delays. Five of the 16 panel members saw their terms expire in January 2026, yet no replacements have been named. Behind the scenes, turnover among Agency for Healthcare Research and Quality (AHRQ) employees—who support the task force's evidence reviews—has further strained operations.

The consequences extend beyond internal processes. Insurers rely on USPSTF grades (A or B) to determine which preventive services, like cancer screenings, must be covered at no cost to patients. Several pending recommendations—including updates on breast cancer medication, chronic kidney disease screening, and HPV testing for cervical cancer—remain in limbo. Even external updates, such as the Health Resources and Services Administration's new cervical cancer screening guidelines (which allow self-collected samples), await USPSTF endorsement for broader adoption.

In response, the American Medical Association has called on Secretary Kennedy to retain the current members and restart regular meetings. Without action, the group warns, millions could face uncertainty over access to essential preventive care.

The USPSTF's reduced output and missed deadlines have left critical health recommendations unresolved. Until the panel resumes full activity, patients and providers may see delays in updated guidelines for screenings, treatments, and insurance coverage. The impact of these hold-ups will depend on whether HHS addresses the staffing gaps and restores the task force's usual schedule.